Cerebrospinal fluid levels of phosphorylated tau and Aβ1-38/Aβ1- 40/Aβ1-42 in Alzheimer's disease with PS1 mutations

Amyloid

Volumn 20, Issue 2, 2013, Pages 107-112

  Ikeda, Masaki ^a   Yonemura, Kimie ^a,b   Kakuda, Satoko ^a   Tashiro, Yuichi ^a   Fujita, Yukio ^a   Takai, Eriko ^a   Hashimoto, Yukiko ^a   Makioka, Kouki ^a   Furuta, Natsumi ^a   Ishiguro, Koichi ^c   Maruki, Risa ^d   Yoshida, Jun'Ichi ^e   Miyaguchi, Osamu ^f   Tsukie, Tamao ^f   Kuwano, Ryouzou ^f   Yamazaki, Tsuneo ^g   Yamaguchi, Haruyasu ^h   Amari, Masakuni ⁱ   Takatama, Masamitsu ⁱ   Harigaya, Yasuo ^j   Okamoto, Koichi ^a   more..

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yukiguni Yamato General Hospital   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Moroyama Hospital   (Japan)

^e Sait Pierre Hospital   (Japan)

^f NIIGATA UNIVERSITY   (Japan)

^g GUNMA UNIVERSITY   (Japan)

^h GUNMA UNIVERSITY   (Japan)

ⁱ GERIATRICS RESEARCH INSTITUTE AND HOSPITAL   (Japan)

^j MAEBASHI RED CROSS HOSPITAL   (Japan)

more..

Author keywords

Alzheimer's disease; Amyloid protein; Cerebrospinal fluid; Phosphorylated tau; Presenilin 1

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-48]; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; PRESENILIN 1; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E2; BIOLOGICAL MARKERS; DEMENTIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PRESENILIN-1; TAU PROTEINS;

EID: 84878317303     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2013.790810     Document Type: Article

References (32)

1. www.metalife.com/OMIM/104300.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
3. Sherrington R, Rogaev EL, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375:754-60.
4. Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, Liang Y, Chi H, et al. Screening for PSEN1 mutations in a referral-based series of AD cases. Neurology 2001;57:621-5.
5. Ikeda M, Sharma V, Sumi SM, Rogaeva EA, Poorkaj P, Sherrington R, Nee L, et al. The clinical phenotypes of two missense mutations in the presenilin 1 gene in Japanese patients. Ann Neurol 1996;40: 912-17.
6. Alzheimer Reasearch Forum.Available from: http://www.alzforu-m.org/.
7. Lee VM, Balin BJ, Otvos Jr L, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991;251:675-8.
8. Ishiguro K, Omori A, Takamatsu M, Sato K, Arioka M, Uchida T, Imahori K. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci Lett 1992;148:202-6.
9. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Abeta1-40, and Abeta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
10. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, et al. Improved discrimination of AD patients using b-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-62.
11. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, Sato K, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270: 91-4.
12. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150-6.
13. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
14. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-96.
15. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006;129:1177-87.
16. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, et al. Cerebrospinal fluid tau, p-tau 181 and amyloid-b38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 2011;31:37-44.
17. Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, et al. CSF amyloid b38 as a novel diagnostic marker for dementia with Lewy bodies. Neurol Neurosurg Psychiatry 2011; 82:160-4.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
19. Holsinger T, Deveau J, Boustani M, Williams JW. Does this patient have dementia? JAMA 2007;297:2391-404.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
21. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stagePCR. Lancet 1991;337:1158-9.
22. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, et al. Differential levels of a-synuclein, b-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010;81:608-10.
23. Ikeda M, Hirayanagi K, Arai M, Kakuda S, Makioka K, Furuta N, Takai E, et al. Encephalopathy with amyloid angiopathy and numerous amyloid plaques with low levels of CSF Ab1-40/Ab1-42. Amyloid 2012;19:186-90.
24. Kakuda N, Shoji M, Arai H, Furukawa K, Ikeuchi T, Akazawa K, Takami M, et al. Altered g-secretase activity in mild cognitive impairment and Alzheimer's disease. EMBO Mol Med 2012;4: 344-52.
25. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, Andreasen N, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
26. Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, et al. Hypothetical model of dynamic bio-markers of the Alzheimer's pathological cascade. Lancet Neurol 2019;9:119-28.
27. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, Klunk WE, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7: 263-9.
28. Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, Blankenstein MA, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007;69: 1006-11.
29. Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener 2010;5:2.
30. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365-70.
31. Ishikawa A, Piao YS, Miyashita A, Kuwano R, Onodera O, Ohtake H, Suzuki M, et al. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann Neurol 2005;57: 429-34.
32. Yoshimoto M, Iwai A, Kang D, Otero D, Xia Y, Saitoh T. NACP, the precursor protein of the non-amyloid b/A4 protein (Ab) component of Alzheimer disease amyloid, binds Ab and stimulates Ab aggregation. Proc Natl Acad Sci USA 1995;92:9141-5.